JNBA Financial Advisors Has $27,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

JNBA Financial Advisors decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 78.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 351 shares of the company’s stock after selling 1,305 shares during the period. JNBA Financial Advisors’ holdings in AstraZeneca were worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. McClarren Financial Advisors Inc. increased its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca in the second quarter valued at $26,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at $29,000. Hobbs Group Advisors LLC bought a new position in shares of AstraZeneca in the second quarter valued at about $35,000. Finally, Versant Capital Management Inc grew its holdings in AstraZeneca by 1,614.8% during the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock worth $36,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen upped their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AZN stock opened at $63.85 on Thursday. The firm’s 50 day moving average price is $78.45 and its two-hundred day moving average price is $78.75. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock has a market cap of $197.97 billion, a PE ratio of 30.85, a PEG ratio of 1.32 and a beta of 0.47.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.